Health is changing fast. We make it make sense.

FDA Approves Journavx: A New Era in Non-Opioid Pain Relief

The FDA has approved Journavx (suzetrigine), a non-opioid pain medication for moderate to severe acute pain. Unlike opioids, it blocks the Nav1.8 sodium channel to interrupt pain signals before reaching the brain, significantly reducing risks of addiction and side effects. This approval marks a pivotal change in pain management practices.

1–2 minutes

Sources and References

FDA. “FDA Approves Journavx, a Non-Opioid Treatment for Acute Pain.” FDA, 2025, FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain | FDA

Northwestern University. “FDA’s Non-Opioid Pain Drug Approval is a Breakthrough.” Northwestern News, 2025, FDA approval of non-opioid pain drug is ‘a major breakthrough,’ expert says: For Journalists – Northwestern University

Science. “New Pain Medication Approved by FDA After 25 Years.” Science, 2025, Nonopioid drug for acute pain wins FDA approval | Science | AAAS

Vertex Pharmaceuticals. “Vertex Announces FDA Approval of Journavx.” Vertex News, 2025, Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain | Vertex Pharmaceuticals Newsroom

Nature. “FDA Approves First Non-Opioid Painkiller in Decades.” Nature, 2025, FDA approves new non-opioid pain drug

.

Leave a comment

Pages: 1 2

Get the UpNEX Health Brief.

A concise, evidence-based briefing on the health stories worth knowing, sent once a month.